For women who require treatment with quetiapine during pregnancy, the available reproductive safety data are generally reassuring. The largest body of evidence does not suggest a meaningful increase in major congenital malformations, while metabolic effects, particularly gestational diabetes, remain an important consideration.
A new study examines pregnancy outcomes among women using stimulants or atomoxetine during pregnancy, finding modest increases in some complications with stimulant use while highlighting important limitations of observational data.
A large claims-based study found no increased risk for most outcomes with first-trimester stimulant exposure during pregnancy, but higher risks when use continued later in pregnancy.
A new cohort study from Australia found that lithium use during pregnancy was linked to a two-fold increased risk of spontaneous preterm birth, along with higher risks of a large for gestational age infant and congenital cardiac malformations. We review how these findings compare with prior research and what they mean for women with bipolar disorder who are using — or considering — lithium during pregnancy.
This study uncovers how trauma, isolation, loss of identity, and lack of support can overlap and amplify each other, deepening despair and driving suicide risk among women in the perinatal period.
While we have adequate data to support the use of SSRI and SNRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. Although we less commonly use mirtazapine in pregnancy, several [...]
In this study with over 4000 infants exposed to gabapentin, the information is reassuring. While we cannot rule out the possibility of a small increase in risk of cardiovascular malformations in gabapentin-exposed infants, gabapentin does not appear to be a major teratogen.Â
In this large observational study, similar and, in some instances, more favorable neonatal and maternal outcomes were observed in pregnancies exposed to buprenorphine combined with naloxone compared to pregnancies exposed to buprenorphine alone.
This large cohort study from Taiwan indicates that the concomitant use of antidepressants and benzodiazepines during the first trimester is not associated with a substantial increase in risk for overall malformations.
There is evidence that depression itself can increase risk for preeclampsia. In women with more severe depression, treatment with an SSRI antidepressant may decrease risk.
